Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.775
-0.065 (-7.70%)
At close: Sep 11, 2024, 4:00 PM
0.820
+0.045 (5.77%)
After-hours: Sep 11, 2024, 4:58 PM EDT
Xilio Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Xilio Therapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for XLO.
Recommendation Trends
| Rating | Dec '22 | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 3 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +802.88% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +802.88% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +1,189.82% | Jan 27, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +802.88% | Dec 21, 2022 |
| Raymond James | Raymond James | Buy Maintains $31 → $13 | Buy | Maintains | $31 → $13 | +1,576.77% | Nov 10, 2022 |
Financial Forecast
Revenue This Year
6.84M
Revenue Next Year
33.06M
from 6.84M
Increased by 383.35%
EPS This Year
-1.27
from -2.78
EPS Next Year
-0.58
from -1.27
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 16.4M | 78.8M | 78.8M | ||
| Avg | 6.8M | 33.1M | 29.5M | ||
| Low | 2.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 1,051.3% | 138.2% | ||
| Avg | - | 383.3% | -10.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.05 | 0.01 | -0.44 | ||
| Avg | -1.27 | -0.58 | -0.55 | ||
| Low | -1.51 | -0.87 | -0.59 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.